Assessment of costs associated with adverse events in patients with cancer
Open Access
- 13 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4), e0196007
- https://doi.org/10.1371/journal.pone.0196007
Abstract
Adverse event (AE)-related costs represent an important component of economic models for cancer care. However, since previous studies mostly focused on specific AEs, treatments, or cancer types, limited information is currently available. Therefore, this study assessed the incremental healthcare costs associated with a large number of AEs among patients diagnosed with some of the most prevalent types of cancer. Data were obtained from a large US claims database. Adult patients were included if diagnosed with and treated for one of the following cancer types: breast, digestive organs and peritoneum, genitourinary organs (including bladder and ovary and other uterine adnexa), lung, lymphatic and hematopoietic tissue, and skin. Treatment episodes were defined as the period from initiation of the first antineoplastic pharmacologic therapy to discontinuation (i.e., gap of ≥ 45 days), or change in treatment regimen, or end of data availability. A total of 36 AEs were selected from the product inserts of 104 treatments recommended by practice guidelines. A retrospective matched cohort design was used, matching a treatment episode with a certain AE with a treatment episode without that AE. A total of 412,005 patients were selected, for a total of 794,243 treatment episodes, resulting in 1,617,368 matched treatment episodes across all 36 AEs. Incremental healthcare costs associated with AEs of any severity ranged from $546 for cough/upper respiratory infections to $24,633 for gastrointestinal perforation. The three most costly AEs when considering any severity were gastrointestinal perforation ($24,633), central nervous system hemorrhage ($24,322), and sepsis/septicemia ($23,510). Incremental healthcare costs associated with severe AEs ranged from $15,709 for dermatitis and rash to $48,538 for gastrointestinal fistula. The three most costly severe AEs were gastrointestinal fistula ($48,538), gastrointestinal perforation ($41,281), and central nervous system hemorrhage ($38,428). In conclusion, AEs during treatment episodes for cancer were frequent and associated with a substantial economic burden.Keywords
This publication has 24 references indexed in Scilit:
- The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United StatesJournal of Medical Economics, 2016
- Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.2016
- New Frameworks to Assess Value of Cancer Care: Strengths and LimitationsThe Oncologist, 2016
- Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care SystemJournal of Managed Care & Specialty Pharmacy, 2015
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World SettingThe Oncologist, 2014
- Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practiceBMC Cancer, 2012
- Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung CancerChemotherapy Research and Practice, 2012
- Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer AgentsArchives of Dermatology, 2011
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005